Drugs in ATC Class N05

Up to Top Level ATC Classes

Up to N - Nervous system

Subclasses in ATC: N05 - PSYCHOLEPTICS

N05A - ANTIPSYCHOTICS

N05B - ANXIOLYTICS

N05C - HYPNOTICS AND SEDATIVES

N05 Market Analysis and Financial Projection

The ATC Class N05 (Psycholeptics) encompasses antipsychotics, anxiolytics, and hypnotics/sedatives, critical for treating conditions like schizophrenia, anxiety, and insomnia. Below is an analysis of market dynamics and patent trends shaping this therapeutic class.

---

Market Dynamics

Growth Drivers

1. Rising Mental Health Burden:

   • The global neuroleptics market is projected to reach USD 15.84 billion by 2028 (CAGR: 2.05% during 2025–2035), driven by increasing psychosis cases linked to substance abuse and genetic factors[3][10].
   • The schizophrenia drugs market alone is expected to grow to USD 10.85 billion by 2029 (CAGR: 6.3%)[11].
   • COVID-19 escalated anxiety and depression rates by 25% globally, boosting demand for hypnotics (N05C) and antipsychotics[16].

2. Cost Pressures and Generics Dominance:

   • Generics account for 83.6% of psycholeptics by volume (DDD/1000/day), but brand-name drugs dominate financially (54.51% share in 2014)[1].
   • Subgroup disparities exist:
     • Hypnotics (N05C): 98.82% generics by volume[1].
     • Antipsychotics (N05A): Generics lead (67.54% by volume), but brand-name formulations like biperiden (N04A) retain 99% market share due to lack of generic alternatives[1][5].

3. Regional Utilization Patterns:

   • Croatia’s antipsychotic consumption decreased by 19.9% (2001–2003), while Scandinavian countries like Denmark saw increases[17].
   • Anxiolytics (N05B) remain widely prescribed, with generics dominating 85.31% of volume globally[1].

---

Patent Landscape

Key Expirations and Innovations

1. Blockbuster Drug Expiries:

   • Abilify Maintena (antipsychotic): Patent expiry in October 2024 will reduce Otsuka’s sales from $1.5 billion (2024) to $459 million by 2029[20].
   • Lumateperone (Caplyta): Patent protections extend until 2039 for key formulations, securing revenue for Intra-Cellular Therapies[4].

2. Psychedelic Therapy Patents:

   • Over 5,000 psychedelic-related patents are anticipated within three years, focusing on synthetic formulations (e.g., psilocybin) and delivery methods[2][6][15].
   • Compass Pathways and Usona Institute hold breakthrough FDA designations for psilocybin therapies, accelerating market entry[2][7].

3. AI-Driven Drug Development:

   • 66% of IP experts predict AI will spur patenting of drug candidates, though challenges like data ownership and inventorship disputes loom[18].
   • Regulatory exclusivity periods (e.g., FDA’s 25-year maximum) remain critical for recouping R&D costs[18].

---

Emerging Trends

1. Non-Traditional Psycholeptics:

   • Melatonin receptor agonists (N05CH) and orexin antagonists (N05CJ) are gaining traction for sleep disorders, with suvorexant and daridorexant as key players[8][19].
   • Psychedelic therapeutics: Market size is forecasted to grow from USD 2.2 billion (2024) to USD 9.6 billion by 2034 (CAGR: 15.6%)[7][15].

2. Geographic Expansion:

   • North America leads due to high mental health awareness, while Asia-Pacific emerges as a growth hotspot with improving healthcare infrastructure[7][15].

---

Challenges

• Side Effects: Long-term antipsychotic use correlates with metabolic syndrome and movement disorders, dampening adherence[3][16].
• Patent Quality: Concerns persist over “low-quality” psychedelic patents, which could inflate costs and delay market access[2][6].
• Generic Competition: Brands face revenue erosion post-patent expiry, exemplified by Abilify’s projected 12% annual sales decline[20].

---

“Patents are good for true innovations. Bad patents are a drag on the system.” – David Casimir, Intellectual Property Lawyer[2].

The psycholeptics market balances growth from mental health demand with pressures from generics and IP complexities. Innovations in AI, psychedelics, and targeted therapies will define its trajectory, while patent cliffs and regulatory hurdles remain pivotal challenges.

References

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC4261909/
2. https://www.vice.com/en/article/can-a-company-patent-the-basic-components-of-psychedelic-therapy/
3. https://www.biospace.com/neuroleptics-market-analysis-statistics-revenue-demand-and-trend-analysis-research-report-by-2028
4. https://www.pharmakb.com/drug-report/lumateperone
5. https://fse.studenttheses.ub.rug.nl/24167/1/Bachelor%20Project,%20Advise%20use%20psychotropic%20drugs%20(2000-2021),%20Van%20der%20Ploeg,%20M%20(S3304523).pdf
6. https://www.repository.law.indiana.edu/cgi/viewcontent.cgi?article=11522&context=ilj
7. https://www.insightaceanalytic.com/report/global-psychedelic-therapeutics-market/1329
8. https://en.wikipedia.org/wiki/ATC_code_N05
9. https://www.5nplus.com/en/news/5n-patents-uniquely-positioned-to-expedite-first-t/
10. https://www.biospace.com/press-releases/psychomotor-agitation-market-predicted-to-grow-at-a-steady-cagr-of-2-05-during-2025-2035-impelled-by-rising-prevalence-of-mental-health-disorders
11. https://health.einnews.com/amp/pr_news/789647402/global-schizophrenia-drugs-market-forecast-2025-2034-analyzing-growth-drivers-market-share-segments-emerging-trends
12. https://drugs.ncats.io/drug/YJ050AQ56X
13. https://www.nber.org/system/files/working_papers/w24957/revisions/w24957.rev1.pdf
14. https://www.knowmade.com/patent-analytics-services/patent-report/gan-electronics-patent-landscape-analysis-2023/
15. https://www.openpr.com/news/3928740/trending-report-on-psychedelic-drugs-market-2025-2032-business
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC10855477/
17. https://hrcak.srce.hr/file/62112
18. https://www.dennemeyer.com/ip-blog/news/ip-trends-in-the-pharmaceutical-industry/
19. https://atcddd.fhi.no/atc_ddd_index/?code=n05
20. https://www.pharmavoice.com/news/drug-patent-expirations-xarelto-abilify-victoza/713384/